वैकल्पिक उत्पाद विश्लेषण
आपकी अनुमति से हम गोपनीयता-सीमित विश्लेषण का उपयोग करके समझते हैं कि कौन-सी शोध यात्राएँ उपयोगी हैं। हम विज्ञापन ट्रैकर या सत्र रिकॉर्डिंग नहीं चलाते। आप यह विकल्प प्राथमिकताओं में बदल सकते हैं। पढ़ें गोपनीयता नीति.
Cencora, Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $65.0B | |
|---|---|---|
| P/E (forward) | 15.7x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2026-09-30 | Trend |
| Revenue | $238.59B | $262.17B | $293.96B | $321.33B | — | +10.4% |
| Gross profit | $8.30B | $8.96B | $9.91B | $11.48B | — | +11.4% |
| Operating income | $2.37B | $2.34B | $2.18B | $2.63B | — | +3.6% |
| Net income | $1.70B | $1.75B | $1.51B | $1.55B | — | -2.9% |
| EPS (diluted) | $8.04 | $8.53 | $7.53 | $7.96 | $13.31 | +13.4% |
| EBITDA | $3.12B | $3.42B | $3.37B | $3.75B | — | +6.2% |
| R&D | — | — | — | — | — | — |
| SG&A | $4.85B | $5.31B | $5.66B | $6.49B | — | +10.2% |
Recent company headlines from major financial publishers.
Specialty pharmaceutical distribution and oncology MSO capabilities accelerate following the integration of American Oncology Network. Top-line revenue compounds at 7.5% to 8.0%, gross margin expands above 3.7%, and operating margin expands toward peer levels of 1.35%. Robust free cash flow accelerates share retirements well beyond the baseline.
Cencora compounds at steady mid-single-digit rates in line with the house schedule, with FY2027 revenue reaching $351.85B and adjusted EPS reaching $19.80. Operating margin normalizes along the 1.22% to 1.30% glide path, while share repurchases reduce diluted share count by 1.5% annually, supporting a fair value of $328.59.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 6.6% | $356 | $364 | $373 | $384 | $395 |
| 7.1% | $335 | $342 | $349 | $357 | $366 |
| 7.6% | $318 | $323 | $329 | $335 | $342 |
| 8.1% | $303 | $307 | $312 | $317 | $322 |
| 8.6% | $289 | $293 | $297 | $301 | $306 |
Upcoming earnings date and setup when available.
हर महीने प्रकाशित शोध संस्करण की रेटिंग। रेटिंग विश्लेषण की तारीख की कीमत की तुलना उचित मूल्य से करती है; यह इस बात का रिकॉर्ड नहीं है कि आकलन सही निकला या नहीं।
| वर्ष | जन॰ | फ़र॰ | मार्च | अप्रैल | मई | जून | जुल॰ | अग॰ | सित॰ | अक्टू॰ | नव॰ | दिस॰ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
